Uploaded on Apr 12, 2024
According to the latest research report by IMARC Group, The United States home infusion therapy market size is projected to exhibit a growth rate (CAGR) of XX% during 2024-2032. More Info:- https://www.imarcgroup.com/united-states-home-infusion-therapy-market
United States Home Infusion Therapy Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
United States Home Infusion Therapy Market Research and Forecast Report 2024-2032 Format: PDF+EXCEL © 2023 IMARC All Rights Reserved About IMARC Group In ternat ional Market Analys is Research and Consul t ing Group is a leading adv iser on management s t rategy and market research wor ldwide. We par tner wi th c l ients in a l l regions and indust ry vert ica ls to ident i fy thei r h ighest -value oppor tuni t ies, address thei r most cr i t ica l chal lenges, and t ransform thei r bus inesses. IMARC’s in format ion products inc lude major market , sc ient i f ic , economic and technological developments for bus iness leaders in pharmaceut ica l , indust r ia l , and h igh technology organizat ions. Market forecasts and indust ry analys is for b iotechnology, advanced mater ia ls , chemicals , food and beverage, t ravel and tour ism, nanotechnology and novel process ing methods are at the top of the company’s exper t ise. IMARC’s ta i lored approach combines unfathomable ins ight in to the dynamics o f companies and markets wi th c lose cooperat ion at a l l levels of the c l ient organizat ion. This ensures that our c l ients achieve unmatchable compet i t ive advantage, bui ld more pro f ic ient organizat ions, and secure las t ing resul ts . Acco r d ing t o t h e l a t es t r epo r t by I M ARC G r oup , t i t l ed " Un i t e d S t a t es Ho me I n f us i on Thera py M a rke t : I ndu st ry T r end s , Sha re , S i ze , G r ow t h , O ppo r t un i t y and For ecas t 20 24 - 20 32 , " t he Un i t ed S t a t es hom e in f us ion t h e r ap y m ar k e t s i z e i s p r o je c t ed t o e xh ib i t a g r ow t h r a t e ( CA G R) o f XX % du r ing 2024 - 203 2 . Report Hom e in f us ion t h e r apy i s a spec ia l i zed hea l t hca r e se r v i ce t ha t a l l ow s pa t i en t s t o r ece i ve i n t r av enous m e d ica t i ons , f l u i ds , and n u t r i e n t s i n t he c om f o r t o f t he i r own hom es . Th is t r ea t m en t m e t ho d is pa r t i cu la r l y bene f i c i a l f o r i nd i v i dua l s w i t h ch r on i c Highlight and i l l nes ses , s e r i ous i n f ec t i ons , o r co m p lex m ed ica l con d i t i on s t ha t r equ i r e ong o ing i n t r a venou s t h e r ap y . Hom e in f u s ion t he r a py i s adm in i s t e r ed b y t r a ined h ea l t h ca r e p r o f e ss iona l s , su ch as Description r eg i s t e r e d nu r ses o r i n f u s ion pha r m ac is t s , w ho v i s i t t he hom e o f t he pa t e in t t o s e t up a nd m anage t he i n f us i on p r ocess . The t he r apy can i n vo l ve a r ang e o f m ed ic a t i o ns , i n c lud in g an t i b io t i c s , pa in m anage m en t d r ug s , che m ot h e r ap y age n t s , im m une g lobu l i n s , a nd nu t r i t i o na l su pp lem en t s . Reque st f o r a P DF s ampl e o f t h i s repor t : h t t p s : / / www. im ar c g r ou p . com / un i t ed - s t a t es - hom e- in f us ion - t he r apy - m ar k e t / r eque s t sa m p l e Report Description U n i t e d S t a t e s H o m e In f u s i o n T h e r a p y M a r k e t T r e n d s : T h e r i s i n g p r e v a l e n c e o f c h r o n i c d i s e a s e s s u c h a s c a n c e r , a u to i mm u n e d i s o r d e r s , a n d i n f e c t i o u s d i s e a s e s i s f u e l i n g t h e d e ma n d f o r h o m e i n f u s i o n t h e r a p y . A s t h e p o p u l a t i o n a g e s a n d l i f e s t y l e s c h a n g e , t h e i n c i d e n c e o f c h r o n i c c o n d i t i o n s r e q u i r i n g l o n g - t e r m i n t r a v e n o u s t h e r a p y i s o n t h e r i s e . H o m e i n f u s i o n t h e r a p y p r o v i d e s t h e s e p a t i e n t s w i t h a c o n v e n i e n t a n d c o m f o r t a b l e a l t e r n a t i v e t o r e c e i v i n g t r e a tm e n t i n a h o s p i t a l o r c l i n i c s e t t i n g . A d d i t i o n a l l y , t h e e s c a l a t i n g h e a l t h c a r e c o s t s a s s o c i a te d w i t h h o s p i t a l - b a s e d c a r e a r e p r o m p t i n g p a t i e n t s , i n s u r e r s , a n d h e a l t h c a r e p r o v i d e r s t o e x p l o r e m o r e c o s t - e f f e c t i v e a l t e r n a t i v e s s u c h a s h o m e i n f u s i o n t h e r a p y . B y s h i f t i n g c e r t a i n t r e a t m e n ts f r o m h o s p i t a l s t o p a t i e n t s ' h o m e s , h e a l t h c a r e s y s t e m s c a n r e d u c e o v e r h e a d e x p e n s e s , i m p r o v e r e s o u r c e a l l o c a t i o n , a n d o p t i m i z e p a t i e n t o u t c o m e s . H o m e i n f u s i o n t h e r a p y o f f e r s p o te n t i a l c o s t s a v i n g s b y m i n i m i z i n g h o s p i t a l s t a y s , d e c r e a s i n g t h e r i s k o f h o s p i t a l - a c q u i r e d i n f e c t i o n s , a n d e n h a n c i n g o v e r a l l e f f i c i e n c y i n t h e h e a l t h c a r e d e l i v e r y s y s t e m . O t h e r t h a n t h i s , t h e g r o w i n g d e m a n d f o r p e r s o n a l i z e d a n d c o n v e n i e n t h e a l t h c a r e s e r v i c e s i s d r i v i n g t h e e x p a n s i o n o f t h e h o m e i n f u s i o n t h e r a p y m a r k e t . P a t i e n t s a r e i n c r e a s i n g l y s e e k i n g t r e a t m e n t s t h a t c a t e r t o t h e i r i n d i v i d u a l n e e d s a n d p r e f e r e n c e s , i n c l u d i n g t h e a b i l i t y t o r e c e i v e c a r e i n t h e c o mf o r t o f t h e i r o w n h o m e s . H o m e i n f u s i o n t h e r a p y a l l o w s p a t i e n t s t o m a i n t a i n t h e i r i n d e p e n d e n c e , a d h e r e t o t h e i r t r e a tm e n t r e g i m e n s m o r e e f f e c t i v e l y , a n d e x p e r i e n c e i m p r o v e d q u a l i t y o f l i f e . M o r e o v e r , s u p p o r t i v e g o v e r n m e n t i n i t i a t i v e s a n d p o l i c i e s a r e c o n t r i b u t i n g t o t h e g r o w th o f t h e h o m e i n f u s i o n t h e r a p y m a r k e t i n t h e U n i t e d S ta t e s . V ie w R e p o r t T O C , F i g u r e s a n d T a b l e s : h t t p s : / / w w w . i m a r c g r o u p . c o m / u n i t e d - s t a t e s - h o m e - i n f u s i o n - t h e r a p y - m a r k e t Product Insights: • Infusion Pumps o Elastomeric o Electromechanical o Gravity o Others • Intravenous Sets Report • IV Cannulas Segmentation • Needleless Connectors Application Insights: • Anti- Infect ive • Endocr inology o Diabetes o Others • Hydrat ion Therapy o Athletes o Others • Chemotherapy • Enteral Nutr i t ion • Parenteral Nutr i t ion • Specialty Pharmaceuticals Report • Others Segmentation Regional Insights: • Northeast • Midwest • South • West How has the United States home infusion therapy market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the United States home infusion therapy market? Key What is the breakup of the United States home infusion therapy market on the basis of product? Questions What is the breakup of the United States home infusion therapy market on the basis of application? Answered in What are the various stages in the value chain of the the Report United States home infusion therapy market? What are the key driving factors and challenges in the United States home infusion therapy? What is the structure of the United States home infusion therapy market and who are the key players? What is the degree of competition in the United States home infusion therapy market? 1 P r e f a c e 2 S c o p e a n d M e t h o d o l o g y 2 . 1 O b j e c t i v e s o f t h e S t u d y 2 . 2 S t a k e h o l d e r s 2 . 3 D a t a S o u r c e s 2 . 3 . 1 P r i m a r y S o u r c e s 2 . 3 . 2 S e c o n d a r y S o u r c e s 2 . 4 M a r k e t E s t i m a t i o n Table of 2 . 4 . 1 B o t t o m - U p A p p r o a c h 2 . 4 . 2 T o p - D o w n A p p r o a c h 2 . 5 F o r e c a s t i n g M e t h o d o l o g y 3 E x e c u t i v e S u m m a r y 4 U n i t e d S t a t e s H o m e I n f u s i o n T h e r a p y M a r k e t - I n t r o d u c t i o n Contents 4 . 1 O v e r v i e w 4 . 2 M a r k e t D y n a m i c s 4 . 3 I n d u s t r y T r e n d s 4 . 4 C o m p e t i t i v e I n t e l l i g e n c e 5 U n i t e d S t a t e s H o m e I n f u s i o n T h e r a p y M a r k e t L a n d s c a p e 5 . 1 H i s t o r i c a l a n d C u r r e n t M a r k e t T r e n d s ( 2 0 1 8 - 2 0 2 3 ) 5 . 2 M a r k e t F o r e c a s t ( 2 0 2 4 - 2 0 3 2 ) 6 U n i t e d S t a t e s H o m e I n f u s i o n T h e r a p y M a r k e t - B r e a k u p b y P r o d u c t 6 . 1 I n f u s i o n P u m p s 6 . 1 . 1 O v e r v i e w 6 . 1 . 2 H i s t o r i c a l a n d C u r r e n t M a r k e t T r e n d s ( 2 0 1 8 - 2 0 2 3 ) 6 . 1 . 3 M a r k e t S e g m e n t a t i o n 6 . 1 . 3 . 1 E l a s t o m e r i c 6 . 1 . 3 . 2 E l e c t r o m e c h a n i c a l 6 . 1 . 3 . 3 G r a v i t y 6 . 1 . 3 .4 O t h e r s 6 . 1 . 4 M a r k e t F o r e c a s t ( 2 0 2 4 - 2 0 3 2 ) 6 . 2 I n t r a v e n o u s S e t s 6 . 2 . 1 O v e r v i e w 6 . 2 . 2 H i s t o r i c a l a n d C u r r e n t M a r k e t T r e n d s ( 2 0 1 8 - 2 0 2 3 ) 6 . 2 . 3 M a r k e t F o r e c a s t ( 2 0 2 4 - 2 0 3 2 ) 6 . 3 IV C a n n u l a s 6 . 3 . 1 O v e r v i e w 6 . 3 . 2 H i s t o r i c a l a n d C u r r e n t M a r k e t T r e n d s ( 2 0 1 8 - 2 0 2 3 ) 6 . 3 . 3 M a r k e t F o r e c a s t ( 2 0 2 4 - 2 0 3 2 ) 6 . 4 N e e d l e l e s s C o n n e c to r s Table of 6 . 4 . 1 O v e r v i e w 6 . 4 . 2 H i s t o r i c a l a n d C u r r e n t M a r k e t T r e n d s ( 2 0 1 8 - 2 0 2 3 ) 6 . 4 . 3 M a r k e t F o r e c a s t ( 2 0 2 4 - 2 0 3 2 ) 7 U n i t e d S t a t e s H o m e In f u s io n T h e r a p y M a r k e t - B r e a k u p b y Contents A p p l i c a t i o n 7 . 1 A n t i - I n f e c t i v e 7 . 1 . 1 O v e r v i e w 7 . 1 . 2 H i s t o r i c a l a n d C u r r e n t M a r k e t T r e n d s ( 2 0 1 8 - 2 0 2 3 ) 7 . 1 . 3 M a r k e t F o r e c a s t ( 2 0 2 4 - 2 0 3 2 ) 7 . 2 E n d o c r i n o l o g y 7 . 2 . 1 O v e r v i e w 7 . 2 . 2 H i s t o r i c a l a n d C u r r e n t M a r k e t T r e n d s ( 2 0 1 8 - 2 0 2 3 ) 7 . 2 . 3 M a r k e t S e g m e n ta t i o n 7 . 2 . 3 .1 D i a b e te s 7 . 2 . 3 . 2 O th e r s 7 . 2 . 4 M a r k e t F o r e c a s t ( 2 0 2 4 - 2 0 3 2 ) F o r m o r e i n f o r m a t io n , v i s i t : ht tps : / /www. imarcgroup .com/un i ted-s ta tes -home- in fus ion - th erapy-marke t / toc Disclaimer © 2023 IMARC Al l R ights Reserved Th is Pub l i ca t ion and a l l i t ’ s con ten ts un less o therw ise men t i oned a re copy r i gh ted in the name o f I n t e rna t i ona l Marke t Ana lys i s Research and Consu l t ing ( IMARC) . No pa r t o f t h i s pub l i ca t ion may be rep roduced , repackaged , red i s t r i bu ted o r res o ld i n who le o r i n any pa r t . The pub l i ca t ion may a l so no t be used i n any f o rm o r by and means g raph i c e lec t ron ic o r mechan ic a l , i nc lud ing pho tocopy ing , reco rd ing , t ap ing o r by i n fo rmat i on s to rage o r re t r ieva l , o r by any o the r f o rm, w i t hou t the exp ress c ons en t o f I n t e rna t iona l Marke t Ana lys i s Research and Consu l t i ng ( IMARC) . Disc la imer : Al l con ten ts and da ta o f t h i s pub l i c a t i on , i nc lud ing fo recas t s , da ta ana lys i s and op in ion have been based on in f o rmat ion and sources be l ieved to be accu ra te and re l iab le a t t he t ime o f pub l i sh ing . In t e rna t i ona l Ma rke t Ana l ys is Research and Consu l t ing makes no rep resen ta t ion o f war ran t y o f any k ind as to t he acc u racy o r comp le teness o f any I n fo rmat i on p rov ided . IMARC accep ts no l i ab i l i t y wha tsoever f o r any los s o r damage resu l t i ng f rom op in ion , e r ro rs o r i naccu rac ies i f any f ound th is pub l i ca t ion . IMARC, IMARC Group and G loba l Therapy I ns igh t Ser i es a re reg is t e red t rademarks o f I n te rna t iona l Marke t Ana lys i s Research and Consu l t ing . A l l o the r t rademarks used i n th i s pub l i ca t i on a re reg i s te red t rademarks o f t he i r r espec t i ve compan ies . Contact Us Visit us at : https://www.imarcgroup.com TELEPHONE: +1-631-791-1145 E-MAIL: [email protected]
Comments